Skip to main content
60°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
42.45
+0.61 (+1.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
Next >
The Latest Analyst Ratings For Ionis Pharmaceuticals
April 09, 2024
Via
Benzinga
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with...
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
February 22, 2024
Via
Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via
Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Via
Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Via
Benzinga
Exposures
Product Safety
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
January 18, 2024
Via
Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
November 17, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
October 23, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
September 27, 2023
Via
Benzinga
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies
December 27, 2023
These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024.
Via
InvestorPlace
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am
Via
Benzinga
Exposures
Product Safety
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
December 22, 2023
Friday, FDA approved AstraZeneca
Via
Benzinga
Exposures
Product Safety
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
December 19, 2023
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...
Via
Benzinga
Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout.
December 19, 2023
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent?
November 10, 2023
Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout.
Via
Chartmill
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
November 02, 2023
Via
Benzinga
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
October 17, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Why Ionis Pharmaceuticals Stock Popped Today
September 26, 2023
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant...
Via
Benzinga
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
September 26, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents...
Via
Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.
Via
Investor's Business Daily
The 7 Most Hated Stocks by Institutional Traders
September 20, 2023
Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future.
Via
InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,
Via
Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
August 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.